Kenvue Inc. (NYSE:KVUE) Position Cut by Mondrian Investment Partners LTD

by · The Cerbat Gem

Mondrian Investment Partners LTD trimmed its stake in Kenvue Inc. (NYSE:KVUE – Free Report) by 18.6% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 5,319,087 shares of the company’s stock after selling 1,212,908 shares during the quarter. Kenvue accounts for approximately 2.0% of Mondrian Investment Partners LTD’s holdings, making the stock its 28th biggest holding. Mondrian Investment Partners LTD’s holdings in Kenvue were worth $113,243,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently added to or reduced their stakes in KVUE. FMR LLC raised its stake in shares of Kenvue by 2.3% during the third quarter. FMR LLC now owns 137,915,493 shares of the company’s stock valued at $3,189,985,000 after purchasing an additional 3,075,019 shares in the last quarter. State Street Corp raised its stake in shares of Kenvue by 16.8% during the third quarter. State Street Corp now owns 127,213,940 shares of the company’s stock valued at $2,942,458,000 after purchasing an additional 18,283,473 shares in the last quarter. Massachusetts Financial Services Co. MA raised its stake in shares of Kenvue by 8.9% during the third quarter. Massachusetts Financial Services Co. MA now owns 86,979,341 shares of the company’s stock valued at $2,011,832,000 after purchasing an additional 7,115,374 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Kenvue by 0.9% during the third quarter. Geode Capital Management LLC now owns 44,677,077 shares of the company’s stock valued at $1,029,810,000 after purchasing an additional 399,846 shares in the last quarter. Finally, Harris Associates L P raised its stake in shares of Kenvue by 7.5% during the third quarter. Harris Associates L P now owns 31,459,511 shares of the company’s stock valued at $727,658,000 after purchasing an additional 2,186,114 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors.

Kenvue Stock Up 0.5 %

Shares of Kenvue stock opened at $23.20 on Friday. The firm has a market cap of $44.33 billion, a price-to-earnings ratio of 43.76, a P/E/G ratio of 2.62 and a beta of 1.25. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69. Kenvue Inc. has a 52-week low of $17.67 and a 52-week high of $24.46. The stock has a 50-day simple moving average of $21.81 and a 200-day simple moving average of $22.37.

Kenvue (NYSE:KVUE – Get Free Report) last announced its quarterly earnings results on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. On average, equities research analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th were issued a $0.205 dividend. The ex-dividend date of this dividend was Wednesday, February 12th. This represents a $0.82 annualized dividend and a yield of 3.54%. Kenvue’s dividend payout ratio (DPR) is currently 154.72%.

Analyst Ratings Changes

A number of brokerages recently weighed in on KVUE. Canaccord Genuity Group lifted their price target on Kenvue from $24.00 to $29.00 and gave the stock a “buy” rating in a research note on Wednesday, March 5th. Barclays dropped their price target on Kenvue from $23.00 to $21.00 and set an “equal weight” rating on the stock in a research note on Friday, January 17th. UBS Group dropped their price target on Kenvue from $23.00 to $21.00 and set a “neutral” rating on the stock in a research note on Friday, February 7th. Deutsche Bank Aktiengesellschaft cut Kenvue from a “buy” rating to a “hold” rating and dropped their price target for the stock from $25.00 to $24.00 in a research note on Thursday, December 12th. Finally, Citigroup dropped their price target on Kenvue from $25.00 to $21.00 and set a “neutral” rating on the stock in a research note on Wednesday, January 15th. One analyst has rated the stock with a sell rating, seven have given a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $23.75.

View Our Latest Stock Report on KVUE

Kenvue Company Profile

(Free Report)

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.

Read More

Want to see what other hedge funds are holding KVUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kenvue Inc. (NYSE:KVUE – Free Report).